Document is current

Article History

Received: 5 December 2025

Accepted: 10 February 2026

First Online: 25 March 2026

Declarations

:

: Guy Fagherazzi (GF) has provided advisory/speaking services and/or has received research grants and/or speaker honoraria from MSD, Sanofi, MSDAvenir, Eli Lilly, Roche, AstraZeneca, Danone Research, Diabeloop, Bristol Myers Squibb, L’Oréal R&D, Abbvie Pharmaceutical, Pfizer, and Vitalaire; Michael Joubert (MJ) declares consultant and/or speaker fees and/or research support from Abbott, Air Liquide Santé International, Amgen, Asdia, Astrazeneca, Bayer, BMS, Boehringer- Ingelheim, Dexcom, Dinno Santé, Glooko, Insulet, Lifescan, Lilly, LVL médical, Medtronic, MSD, Nestle HomeCare, Novonordisk, Organon, Orkyn, Roche Diabetes, Sanofi, Tandem, Vitalaire, Voluntis, Ypsomed. Michael Joubert is an Editorial Board member of Diabetes Therapy . Michael Joubert was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.; Pierre Serusclat (PS) has provided advisory/speaking services and/or research support from Roche Diabetes Care as an expert on the scientific committee of the present study; Cécile Berteau (CB) and Antoine Pouyet (AP) are employees of Roche Diagnostics France and Timkl France, respectively; Oriane Bretin (OB), Emilie Casarotto (EC), Yolaine Rabat (YR), Pascaline Rabiéga (PR) and Barbara Roux (BR) are employees of IQVIA RWS France and declare no conflicts of interest in relation to this study.

: The study was approved by the French Data Protection Supervisory Authority « Commission Nationale Informatique et Libertés» (CNIL) (authorization no 919119). As this was a retrospective registry-based analysis with pseudonymization, additional consent from individual patients was not required and therefore not obtained. Retrospective analysis of pseudonymized data and therefore, consent for publication is not required.